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Abstract
Background: Exhaled nitric oxide is a non-invasive marker of airway inflammation and a portable analyser, the NIOX 
MINO (Aerocrine AB, Solna, Sweden), is now available. This study aimed to assess the reproducibility of the NIOX MINO 
measurements across age, sex and lung function for both absolute and categorical exhaled nitric oxide values in two 
distinct groups of children and teenagers.
Methods: Paired exhaled nitric oxide readings were obtained from 494 teenagers, aged 16-18 years, enrolled in an 
unselected birth cohort and 65 young people, aged 6-17 years, with asthma enrolled in an interventional asthma 
management study.
Results: The birth cohort participants showed a high degree of variability between first and second exhaled nitric 
oxide readings (mean intra-participant difference 1.37 ppb, 95% limits of agreement -7.61 to 10.34 ppb), although there 
was very close agreement when values were categorised as low, normal, intermediate or high (kappa = 0.907, p < 
0.001). Similar findings were seen in subgroup analyses by sex, lung function and asthma status. Similar findings were 
seen in the interventional study participants.
Conclusions: The reproducibility of exhaled nitric oxide is poor for absolute values but acceptable when values are 
categorised as low, normal, intermediate or high in children and teenagers. One measurement is therefore sufficient 
when using categorical exhaled nitric oxide values to direct asthma management but a mean of at least two 
measurements is required for absolute values.
Introduction
Asthma is a chronic inflammatory disorder of the airways
associated with airway hyperresponsiveness and recur-
rent episodes of reversible airflow limitation that are
accompanied by wheeze, shortness of breath, chest tight-
ness and cough [1]. It is the most common chronic condi-
tion of childhood [2] affecting approximately 20% of
school-aged children in the United Kingdom [3]. Deci-
sions regarding asthma management are currently based
on symptoms and conventional lung function tests.
Exhaled nitric oxide (FeNO) has recently emerged as a
potentially useful tool in the assessment of patients with
asthma [4]. Exhaled nitric oxide measurements correlate
well with measures of airway inflammation, including
sputum levels of eosinophils [5], airway eosinophilia in
bronchial biopsies [6] and allergen exposure [7]. Mea-
surements can be made within minutes, even in young
school children. Furthermore, FeNO has been shown to
rise prior to asthma exacerbations [8] and decrease fol-
lowing administration of inhaled corticosteroids [9] or
leukotriene receptor antagonists [10]. Potential applica-
tions for FeNO may therefore be found in the diagnostic
work up of patients with possible asthma, monitoring of
treatment responses, adherence with treatment and pre-
diction of exacerbations [4,11]. Its role in directing the
chronic management of asthma has though been ques-
tioned recently [12,13]. Previously, FeNO measurement
required static, chemiluminesence-based NO analysers,
such as the NIOX Nitric Oxide Monitoring System
(Aerocrine AB, Solna, Sweden). The use of these analy-
sers in routine clinical practice is, however, limited by
their size and expense. A portable hand-held NO-analy-
ser, the NIOX MINO Asthma Inflammation Monitor
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cal sensors to measure FeNO levels, is now available. This
is ideally suited for use in primary care, where the major-
ity of asthma patients are managed [14].
Studies comparing the performance of the NIOX
MINO and the NIOX have shown that the level of agree-
ment between the two devices is clinically acceptable [15-
18] and the NIOX MINO is now approved by the Federal
Drugs Administration in the United States for assessing
asthma-related airway inflammation [19]. The manufac-
turer recommends that one measurement is sufficient
when using the NIOX MINO [20] rather than two as rec-
ommended in the latest ATS/ERS guidelines [4]. The
manufacturer states an accuracy of ±5 ppb of measured
value below 50 ppb and ±10% at or above 50 ppb [20].
There are a number of studies that support this recom-
mendation of a single measurement [15,16,21,22], how-
ever, to date only one small paediatric study has
addressed this question [18]. In this study of fifty-five
children aged 4-15 years, the first acceptable FeNO mea-
surement obtained using the NIOX MINO was not sig-
nificantly different from the mean of all measurements
(24 versus 27 ppb, p > 0.5) but the median coefficient of
variation for the NIOX MINO was 7.4% (range: 0-44.6)
suggesting that one FeNO measurement is not sufficient
when using the NIOX MINO. The aim of the current val-
idation study was to assess the reproducibility of NIOX
MINO measurements in children and teenagers across
age, sex and lung function, in terms of both the absolute
and categorical FeNO values.
Methods
Study design and participants
In this validation study, the reproducibility of NIOX
MINO measurements was assessed in two separate pop-
ulations.
Unselected, community-based, birth cohort
The birth cohort consisting of teenagers aged 16-18 years
enrolled in a whole population birth cohort (Research
ethics reference 06/Q1701/34) of 1536 infants born on
the Isle of Wight, United Kingdom in 1989/1990 to inves-
tigate the natural history of asthma and allergic disorders.
All these teenagers were assessed with questionnaires,
FeNO measurements, spirometry and skin prick testing.
In accordance with the ATS/ERS guidelines [4], FeNO
measurements (NIOX MINO, Aerocrine AB, Solna, Swe-
den) were performed prior to spirometric testing with
participants standing. The NIOX MINO 300 sensor was
used with the sensor being changed after 300 measure-
ments. Participants were asked to inhale to total lung
capacity through the NIOX MINO and then exhale for 10
seconds at 50 ml/sec (assisted by visual and auditory
cues). Spirometry (KoKo, nSpire Health, Hertford, United
Kingdom) was performed according to the ATS/ERS
guidelines [23]. FEV1 was recorded as percent predicted
for age, height, sex and ethnic origin. Skin prick testing
was performed by a standardised method [24] to a panel
of common allergens: house dust mite (Dermatophagoi-
des pteronyssinus), grass pollen mix, tree pollen mix, cat
and dog epithelia, Alternaria alternata, Cladosporium
herbarum, milk, hens' egg, wheat, soya, cod and peanut as
well as histamine and physiological saline (Alk-Abello,
Horsholm, Denmark). Single-headed lancets were used
and the skin pricked at an angle of 90°. The wheal diame-
ter was recorded at 15 minutes.
Interventional asthma study
This multi-centre study was designed to investigate
whether monitoring FeNO levels can improve the man-
agement of children with asthma (Research ethics refer-
ence 06/Q1702/9). The study sites were Southampton
University Hospital NHS Trust, St Mary's Hospital in
Newport on the Isle of Wight and St Mary's Hospital in
Portsmouth. Inclusion criteria for the interventional
study were age 6-17 years, clinical diagnosis of asthma
(based on typical symptoms, at least a 15% increase in
FEV1 (forced expiratory volume in 1 second) with bron-
chodilator or at least 15% diurnal variability in PEF rates)
and receiving treatment with at least 400 mcg beclom-
ethasone equivalent daily. Exclusion criteria were ciga-
rette smoking, poor adherence with medication, previous
life-threatening exacerbations or the need for mainte-
nance oral prednisolone. In the intervention study, par-
ticipants were assessed 2-monthly for a year. The
spirometry data (KoKo, nSpire Health, Hertford, United
Kingdom) and two FeNO measurements (NIOX MINO,
Aerocrine AB, Solna, Sweden) used in this study were
obtained at the same visit. Both were measured as per the
cohort participants. Demographic details, asthma his-
tory, asthma treatment and history of other atopic dis-
eases were recorded for all participants. Skin prick testing
was performed as per the cohort participants to a grass
pollen mix, tree pollen mix, cat, dog, house dust mite,
saline and histamine (ALK-Abello, Horsholm, Denmark).
A single wheal of at least 3 mm was considered indicative
of atopy in the presence of appropriate negative and posi-
tive control results.
Statistical Analysis
Data were transferred to SPSS version 15 for analysis.
Bland-Altman plots were constructed to assess the
degree of agreement between the absolute values of
paired FeNO readings measured using the NIOX MINO.
FeNO were logarithmically transformed to normalise the
data. Cohen's Kappa was used to assess the degree of
agreement between paired categorical NIOX MINO
measurements. Nitric oxide values were categorised as
low, normal, intermediate or high according to the refer-
ence ranges for age less than 12 years and 12 years or
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analyses were undertaken for males and females, partici-
pants with low and high FEV1 values, older and younger
participants and participants with and without asthma.
Results
Birth cohort
Study participants
Paired NIOX MINO measurements were obtained from
494 of the participants enrolled in the 17 year follow-up
study up to 11th December 2007. Of these, 71 were classi-
fied as having current asthma on the basis of positive
responses to both ISAAC validated questions 'Have you
ever been diagnosed with asthma by a physician?', and,
'Have you had wheezing or whistling in the chest in the
last 12 months?'. The demographic and clinical charac-
teristics of the participants in this population alongside
those of the intervention study participants are shown in
Table 2.
Reproducibility of the absolute value of FeNO
Although a statistically significant linear association was
found between the first and second FeNO readings in
individual participants (Pearson's correlation coefficient
= 0.980, p < 0.001), a Bland-Altman plot showed a high
degree of variability between these paired NIOX MINO
measurements (Figure 1). The mean intra-participant dif-
ference in FeNO (second FeNO reading minus first FeNO
reading) was 1.37 ppb, suggesting that the second FeNO
reading in each participant was on average higher than
the first. This difference was statistically different from
zero (one sample t-test, p < 0.001). The 95% limits of
agreement of -7.61 to 10.34 ppb imply that if two NIOX
MINO measurements are undertaken in the same assess-
ment, there is a 95% chance that the second FeNO value
will be up to 10 ppb above or 8 ppb below the first. Much
of this variability occurs at higher FeNO levels (Figure 1)
and, when subjects with FeNO values above 75 ppb were
excluded from the analysis, the mean intra-participant
difference in FeNO was 0.90 ppb and the 95% limits of
agreement were -4.89 to 6.70 ppb. Similar findings were
seen in subgroup analyses for males and females, partici-
pants with an FEV1 in the lowest and highest tertiles, and
participants with and without asthma (Table 3). In partic-
ipants with asthma, the mean intra-participant difference
in FeNO was 2.37 ppb and the 95% limits of agreement
were -11.38 to 16.12 ppb.
Reproducibility of categorical FeNO values
When FeNO values were categorised as low, normal,
intermediate or high (using <12 or ≥12 year values as
appropriate), very close agreement between paired NIOX
MINO measurements in individual participants was
observed (Kappa (κ) = 0.907, p < 0.001) (Table 4). In the
planned subgroup analyses, very close agreement was
seen in males (κ = 0.894, p < 0.001) and females (κ =
0.919, p < 0.001), participants with an FEV1 in the lowest
(κ = 0.943, p < 0.001) and highest (κ = 0.872, p < 0.001)
tertiles, and in those with current asthma (κ = 0.935, p <
0.001).
Intervention study
Paired FeNO readings were obtained from 65 of the par-
ticipants enrolled in the intervention study. The charac-
teristics of these participants are outlined in Table 2, all
had typical symptoms of asthma. As expected, these par-
ticipants had more severe asthma and were more likely to
be atopic.
Reproducibility of the absolute value of FeNO
Once again, there was a statistically significant linear
association between the first and second FeNO readings
in individual participants (Pearson's correlation coeffi-
cient = 0.977, p < 0.001). Although the mean intra-partic-
ipant difference in FeNO for all participants was only 0.31
ppb, which was not different from zero (one sample t-
test, p = 0.740), the 95% limits of agreement were widely
Table 1: Guide to interpreting FeNO values.
FeNO (ppb)
Children (<12 years) Adults (≥12 years)
Low <5 <5
Normal 5-20 5-25
Intermediate 20-35 25-50
High >35 >50
Categories based on Taylor et al [25,27].
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Table 2: Clinical and demographic characteristics of the study participants.
Birth cohort participants*
All participants Participants with 
asthma
Non-asthmatic 
participants
Intervention study 
participants
(n = 494) (n = 71) (n = 401) (n = 65)
Age (years), mean 
(range)
17.17 (16-18) 17.21 (16-18) 17.16 (16-18) 11 (6-16)
Sex, no. (%)
Male 251 (50.8) 36 (50.7) 207 (51.6) 38 (58.5)
Female 243 (49.2) 35 (49.3) 194 (48.4) 27 (41.5)
Hay fever, no. (%) 183 (37.0) 49 (69.0) 125 (31.2) 56 (86.2)
Eczema, no. (%) 82 (16.6) 24 (33.8) 56 (14.0) 38 (58.5)
Atopy (as defined by 
skin prick testing), 
no. (%) **
195 (42.1) 48 (72.7) 141 (37.3) 37/42 (88.1)
FEV1(% predicted), 
mean (SD)
104.58 (13.22) 97.34 (15.38) 105.99 (12.28) 90.35 (14.57)
FeNO (ppb), median 
(interquartile range) 
***
16 (11-31) 40 (16-74) 15 (11-25.5) 35 (13.5-57.0)
Asthma treatment, 
no. (%)
Inhaled 
corticosteroids
NA 34 (47.9) NA 65 (100)
Short-acting 
bronchodilators
46 (64.8) 65 (100)
Long-acting 
bronchodilators
12 (16.9) 48 (73.8)
Montelukast 1 (1.4) 36 (55.4)
Theophylline 0 (0) 3 (4.6)
*Some of the birth cohort participants could not be categorised because not all questions were answered. NA: Not applicable.
** Percentages are based on the number of participants in whom skin prick testing was performed.
*** Values are based on the first FeNO reading obtained in each participant.
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of agreement were observed in males, participants in the
highest tertile for age and participants with an FEV1 in
the lowest tertile (Table 5). When FeNO values above 75
ppb were excluded the intra-participant difference in
FeNO was 0.64 ppb with 95% limits of agreement of -8.35
to 9.62 ppb.
Reproducibility of categorical FeNO values
For all participants, a Kappa value (κ) of 0.879 (p < 0.001)
was ascertained, suggesting very close agreement
between the first and second FeNO readings in individual
participants when FeNO values were categorised as low,
normal, intermediate or high (Table 6). A similarly high
degree of agreement between categorical FeNO values
was observed in males (κ = 0.823, p < 0.001) and females
(κ = 0.940, p < 0.001), participants in the lowest tertile for
age (κ = 0.921, p < 0.001) and participants with an FEV1 in
the lowest (κ = 0.845, p < 0.001) and highest (κ = 1.000, p
< 0.001) tertiles. It was lower for participants in the high-
est tertile for age (κ = 0.667, p < 0.001), although even in
this group, agreement was reasonable.
Discussion
This study aimed to validate the reproducibility of a new,
portable NO-analyser (the NIOX MINO, Aerocrine AB,
Solna, Sweden) in children and teenagers. The results
from two complementary groups of children and teenag-
ers indicate that the reproducibility of NIOX MINO mea-
surements across the paediatric age range is poor when
considering the absolute value FeNO but is acceptable
when FeNO values are categorised as low, normal, inter-
mediate or high. This suggests that if clinical decisions in
future are based on specific cut-off values of FeNO, the
mean of at least two FeNO measurements should be
reported when using the NIOX MINO. However, for
treatment algorithms based on FeNO categories, one
NIOX MINO measurement would be sufficient, saving
cost and time in clinic. This study is the largest of its kind
Table 3: Subgroup analyses of the reproducibility of the absolute value of FeNO in the birth cohort participants.
Mean intra-participant 
difference in FeNO (ppb) 
(95% CI) [p-value] *
Standard deviation (SD) of 
the intra-participant 
difference in FeNO (ppb)
95% limits of agreement 
(ppb)
All participants 1.37 4.58 -7.61 to 10.34
(n = 494) (0.96, 1.77) [<0.001]
Males 1.43 4.97 -8.30 to 11.17
(n = 251) (0.82, 2.05) [<0.001]
Females 1.30 4.15 -6.83 to 9.43
(n = 243) (0.77, 1.82) [<0.001]
Participants with a low FEV1 2.01 5.21 -8.20 to 12.22
(n = 162) (1.20, 2.81) [<0.001]
Participants with a high 
FEV1
1.07 3.75 -6.28 to 8.42
(n = 162) (0.49, 1.65) [<0.001]
Participants with asthma 2.37 7.01 -11.38 to 16.12
(n = 71) (0.71, 4.03) [0.006]
All others participants 1.19 4.09 -6.82 to 9.20
(n = 401) (0.79, 1.59) [<0.001]
A low FEV1 implies an FEV1in the lowest tercile for the birth cohort participants (less than 98.94% predicted), whilst a high FEV1 implies an 
FEV1in the highest tercile for all the birth cohort participants (greater than 109.80% predicted).
95% limits of agreement = Mean intra-participant difference in FeNO ± 1.96 (SD)
* For comparison of the mean intra-participant difference in FeNO in each group against zero (one sample t-test).
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characteristics on reproducibility of NIOX MINO mea-
surements.
Our findings contradict those of other studies, which
have reported excellent reproducibility of the absolute
value of FeNO measurements obtained using the NIOX
MINO [15,16,21,22]. These studies have, however,
included both adults and children, so their results do not
validate the use of the NIOX MINO in paediatric prac-
tice. Much of this intra-subject variability is seen at
higher levels of FeNO and so it may be more patient
related than monitor related [26] and unlikely to cause
any indecision about clinical management. For the inter-
vention asthma study participants, the reproducibility of
the absolute value of FeNO was poorer in those with a
low FEV1 whilst in the birth cohort participants, greater
variability was observed in participants with asthma.
These are precisely the participants in whom FeNO mea-
surement would be performed in clinical practice. Our
results therefore support McGill's recommendation that
the mean of at least two FeNO measurements should be
used when reporting absolute values using the NIOX
MINO with children and teenagers [18]. It has been sug-
gested that greater variability between FeNO measure-
ments is more likely in those who are not consistently
able to record FeNO [18]. Given that the success rate with
the NIOX MINO increases with age [15], it is therefore
surprising that we observed closer agreement between
paired NIOX MINO measurements in the youngest par-
ticipants (Table 5). Potentially, taking the average of three
or more measurements may have further increased the
reliability of the FeNO value but this was outside the
scope of this study. The other potential limitation of this
study is that a gold standard measure of FeNO, such as
the NIOX monitor (Aerocrine AB, Solna, Sweden) was
not included; again this was outside the scope of this
study which was focusing on the reproducibility of NIOX
Figure 1 Bland Altman plot showing the difference between each 
subject's two FeNO NIOX MINO measurements in the birth co-
hort. Each point represents the absolute difference between the first 
and second FeNO measurements for each participant versus the mean 
of these two measurements (n = 494). Reference lines correspond to 
the mean difference in two FeNO measurements taken in one individ-
ual and the 95%.
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Table 4: Agreement between paired NIOX MINO measurements in the birth cohort participants when FeNO values were 
categorised as low, normal, intermediate or high.
First FeNO reading
Low Normal Intermediate High Total
Second FeNO 
reading
Low 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Normal 0 (0%) 334 (97%) 3 (4%) 0 (0%) 337 (68%)
Intermediate 0 (0%) 10 (3%)) 72 (87%) 1 (2%) 83 (17%)
High 0 (0%) 0 (0%) 8 (10%) 66 (99%) 74 (15%)
Total 0 (0%) 344 (100%) 83 (100%) 67 (100%) 494 (100%)
Cohen's Kappa (κ) = 0.907 (p < 0.001)
Figures represent numbers of participants (% by column). Categories are presented in Table 1.
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validity.
No previous studies have evaluated the reproducibility
of categorical FeNO values obtained using the NIOX
MINO. Our data suggests that the reproducibility of this
approach is acceptable although 10% of subjects may be
misclassified by one category. These categories are based
on cut off values from a number of studies [25,27] and
there may be a certain amount of imprecision in the
boundaries chosen. The small amount of misclassifica-
tion bias is likely to be of minimal clinical importance
unless FeNO levels are being used in isolation to diagnose
asthma [28] or direct the clinical management of patients
with asthma [4]. Different research groups are, however,
using different cut off values, so it is important to assess
whether reproducibility is comparable with other cut off
values. Additionally, future research should seek to deter-
mine whether the accuracy of NIOX MINO measure-
ments is affected by the number of attempts required to
record FeNO, as this would have implications for the
Table 5: Subgroup analyses of the reproducibility of the absolute value of FeNO in the intervention study participants.
Mean intraparticipant difference in 
FeNO (ppb) (95% CI) [p-value] *
Standard deviation (SD) of the intra-
participant difference in FeNO (ppb)
95% limits of agreement 
(ppb)
All participants 0.31 7.45 -14.28 to 14.90
(n = 65) (1.54, 2.15) [0.740]
Males -0.26 9.39 -18.66 to 18.14
(n = 38) (-3.35, 2.82) [0.864]
Females 1.11 3.14 -5.05 to 7.27
(n = 27) (-0.13, 2.35) [0.078]
Youngest participants -0.09 4.08 -8.09 to 7.91
(n = 22) (-1.9, 1.72) [0.918]
Oldest participants 1.10 12.07 -22.55 to 24.75
(n = 21) (-4.40, 6.89) [0.682]
Participants with a low FEV1 -1.45 11.19 -23.38 to 20.48
(n = 22) (-6.42, 3.51) [0.549]
Participants with a high FEV1 0.15 3.28 -6.28 to 6.58
(n = 20) (-1.39, 1.69) [0.840]
A low FEV1 implies an FEV1within the lowest tercile for the intervention study participants (less than 83% predicted), whilst a high FEV1 implies an FEV1within the 
highest tercile for the intervention study participants (greater than 95% predicted).
The youngest participants are those within the lowest tercile for age (less than 10 years 7 months), whilst the oldest participants are those within the highest tercile 
for age (greater than 12 years 8 months).
95% limits of agreement = Mean intra-participant difference in FeNO ± 1.96 (SD)
* For comparison of the mean intra-participant difference in FeNO in each group against zero (one sample t-test).
Figure 2 Bland Altman plot showing the difference between each 
subject's two FeNO NIOX MINO measurements in the interven-
tion study. Each point represents the absolute difference between the 
first and second FeNO measurements for each participant versus the 
mean of these two measurements (n = 65). Reference lines correspond 
to the mean difference in two FeNO measurements taken in one indi-
vidual and the 95% limits of agreement. The normal range of FeNO 
measurements is 5 to 20 ppb in children <12 years and 5 to 25 ppb in 
Mean of each subject’s two FeNO readings (ppb)
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tice. This is particularly important for patients less than
12 years of age who often need more attempts and were
relatively poorly represented in our study. Lastly, given
the number of influences on FeNO levels, these measure-
ment may proved to be most useful when standardised to
the patient's baseline FeNO level while their asthma is
well controlled as we have previously suggested [7]. Such
a strategy would necessitate a further look at the conse-
quences of relying on a single estimate of the level of
FeNO in driving clinical management.
In summary, the NIOX MINO could improve the man-
agement of children with asthma by enabling physicians
to monitor underlying airway inflammation more easily
than has been possible to date. According to the manu-
facturer (Aerocrine AB, Solna, Sweden), one FeNO mea-
surement is sufficient when using the NIOX MINO,
instead of two as recommended by the ATS/ERS guide-
lines. This study has found that in two distinct groups of
children and teenagers, one NIOX MINO measurement
is acceptable when using FeNO to direct asthma manage-
ment, based on FeNO categories, but when using the
absolute value of FeNO, the mean of at least two NIOX
MINO measurements should be used.
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Table 6: Agreement between paired NIOX MINO measurements in the intervention study participants when FeNO values 
were categorised as low, normal, intermediate or high.
First FeNO reading
Low Normal Intermediate High Total
Second FeNO 
reading
Low 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Normal 1 (100%) 22 (96%) 0 (0%) 0 (0%) 23 (35%)
Intermediat
e
0 (0%) 1 (4%) 12 (80%) 1 (4%) 14 (22%)
High 0 (0%) 0 (0%) 3 (20%) 25 (96%) 28 (43%)
Total 1 (100%) 23 (100%) 15 (100%) 26 (100%) 65 (100%)
Cohen's Kappa (κ) = 0.879 (p < 0.001)
Figures represent numbers of participants (% by column). Categories are presented in Table 1 with the <12 or ≥12 year categorical values 
being used as appropriate for individual participants.
Selby et al. Respiratory Research 2010, 11:43
http://respiratory-research.com/content/11/1/43
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